182 related articles for article (PubMed ID: 10385693)
1. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs.
Benford HL; Frith JC; Auriola S; Mönkkönen J; Rogers MJ
Mol Pharmacol; 1999 Jul; 56(1):131-40. PubMed ID: 10385693
[TBL] [Abstract][Full Text] [Related]
2. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
[TBL] [Abstract][Full Text] [Related]
3. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
Fisher JE; Rogers MJ; Halasy JM; Luckman SP; Hughes DE; Masarachia PJ; Wesolowski G; Russell RG; Rodan GA; Reszka AA
Proc Natl Acad Sci U S A; 1999 Jan; 96(1):133-8. PubMed ID: 9874784
[TBL] [Abstract][Full Text] [Related]
4. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.
Lehenkari PP; Kellinsalmi M; Näpänkangas JP; Ylitalo KV; Mönkkönen J; Rogers MJ; Azhayev A; Väänänen HK; Hassinen IE
Mol Pharmacol; 2002 May; 61(5):1255-62. PubMed ID: 11961144
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase.
Reszka AA; Halasy-Nagy JM; Masarachia PJ; Rodan GA
J Biol Chem; 1999 Dec; 274(49):34967-73. PubMed ID: 10574973
[TBL] [Abstract][Full Text] [Related]
6. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
Frith JC; Rogers MJ
J Bone Miner Res; 2003 Feb; 18(2):204-12. PubMed ID: 12568397
[TBL] [Abstract][Full Text] [Related]
7. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.
Benford HL; McGowan NW; Helfrich MH; Nuttall ME; Rogers MJ
Bone; 2001 May; 28(5):465-73. PubMed ID: 11344045
[TBL] [Abstract][Full Text] [Related]
8. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs.
Coxon FP; Benford HL; Russell RG; Rogers MJ
Mol Pharmacol; 1998 Oct; 54(4):631-8. PubMed ID: 9765505
[TBL] [Abstract][Full Text] [Related]
9. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG; Rogers MJ
Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro.
Töyräs A; Ollikainen J; Taskinen M; Mönkkönen J
Eur J Pharm Sci; 2003 Jul; 19(4):223-30. PubMed ID: 12885386
[TBL] [Abstract][Full Text] [Related]
12. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
van beek E; Löwik C; van der Pluijm G; Papapoulos S
J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
14. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
Shipman CM; Croucher PI; Russell RG; Helfrich MH; Rogers MJ
Cancer Res; 1998 Dec; 58(23):5294-7. PubMed ID: 9850051
[TBL] [Abstract][Full Text] [Related]
15. New insights into the molecular mechanisms of action of bisphosphonates.
Rogers MJ
Curr Pharm Des; 2003; 9(32):2643-58. PubMed ID: 14529538
[TBL] [Abstract][Full Text] [Related]
16. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.
Suri S; Mönkkönen J; Taskinen M; Pesonen J; Blank MA; Phipps RJ; Rogers MJ
Bone; 2001 Oct; 29(4):336-43. PubMed ID: 11595616
[TBL] [Abstract][Full Text] [Related]
17. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.
Frith JC; Mönkkönen J; Blackburn GM; Russell RG; Rogers MJ
J Bone Miner Res; 1997 Sep; 12(9):1358-67. PubMed ID: 9286751
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth.
Mönkkönen H; Kuokkanen J; Holen I; Evans A; Lefley DV; Jauhiainen M; Auriola S; Mönkkönen J
Anticancer Drugs; 2008 Apr; 19(4):391-9. PubMed ID: 18454049
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.
Halasy-Nagy JM; Rodan GA; Reszka AA
Bone; 2001 Dec; 29(6):553-9. PubMed ID: 11728926
[TBL] [Abstract][Full Text] [Related]
20. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
